A scDb-Based Trivalent Bispecific Antibody for T-Cell-Mediated Killing of HER3-Expressing Cancer Cells

Researchers developed bispecific antibodies for T-cell retargeting to HER3-expressing tumor cells, utilizing either a single-chain diabody format (scDb) with one binding site for HER3 and one for CD3 on T-cells or a trivalent bispecific scDb-scFv fusion protein exhibiting an additional binding site for HER3.